Anteris Technologies Global Corp. (AVR)
NASDAQ: AVR · Real-Time Price · USD
4.400
-0.420 (-8.71%)
At close: Oct 29, 2025, 4:00 PM EDT
4.400
0.00 (0.00%)
Pre-market: Oct 30, 2025, 9:27 AM EDT
AVR Revenue
Anteris Technologies Global had revenue of $618.00K in the quarter ending June 30, 2025, a decrease of -2.22%. This brings the company's revenue in the last twelve months to $2.48M, down -2.45% year-over-year. In the year 2024, Anteris Technologies Global had annual revenue of $2.70M, down -1.17%.
Revenue (ttm)
$2.48M
Revenue Growth
-2.45%
P/S Ratio
72.16
Revenue / Employee
$18,228
Employees
136
Market Cap
178.88M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70M | -32.00K | -1.17% |
| Dec 31, 2023 | 2.74M | -384.72K | -12.33% |
| Dec 31, 2022 | 3.12M | -2.55M | -44.93% |
| Dec 31, 2021 | 5.66M | 203.73K | 3.73% |
| Dec 31, 2020 | 5.46M | -6.54M | -54.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AVR News
- 2 days ago - Anteris Technologies Announces First Patients Treated in DurAVR® THV Global Pivotal Trial (the “PARADIGM Trial”) - GlobeNewsWire
- 3 days ago - Anteris Technologies Announces One-Year Clinical Outcomes for DurAVR® THV to be Presented at TCT® 2025 - GlobeNewsWire
- 5 weeks ago - Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders - GlobeNewsWire
- 7 weeks ago - Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders - GlobeNewsWire
- 2 months ago - Anteris Announces Results for the Second Quarter of 2025 - GlobeNewsWire
- 5 months ago - Anteris Appoints David Roberts and Gregory Moss to its Board of Directors - GlobeNewsWire
- 7 months ago - Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR® THV - GlobeNewsWire
- 7 months ago - Anteris Reports One-Year Patient Outcomes for DurAVR® THV - GlobeNewsWire